Literature DB >> 3308722

Scleroderma-polymyositis overlap syndrome. Clinical and serologic aspects.

T Mimori1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3308722     DOI： 10.1111/j.1365-4362.1987.tb00580.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  5 in total

1.  A localised morphoea/idiopathic polymyositis overlap.

Authors:  H M al Attia; H Ezzeddin; T Khader; M A Aref
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

Review 2.  Role of MRI in diagnosis and management of idiopathic inflammatory myopathies.

Authors:  Britta Maurer; Ulrich A Walker
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

Review 3.  Muscle involvement in systemic sclerosis: points to consider in clinical trials.

Authors:  Ulrich A Walker; Philip J Clements; Yannick Allanore; Oliver Distler; Chester V Oddis; Dinesh Khanna; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

4.  Genetic association study of TNFAIP3, IFIH1, IRF5 polymorphisms with polymyositis/dermatomyositis in Chinese Han population.

Authors:  Si Chen; Qian Wang; Ziyan Wu; Yuan Li; Ping Li; Fei Sun; Wenjie Zheng; Qingjun Wu; Chanyuan Wu; Chuiwen Deng; Fengchun Zhang; Yongzhe Li
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

5.  Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology.

Authors:  Kavish J Bhansing; Martin Lammens; Hanneke K A Knaapen; Piet L C M van Riel; Baziel G M van Engelen; Madelon C Vonk
Journal:  Arthritis Res Ther       Date:  2014-05-13       Impact factor: 5.156
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.